Literature DB >> 32039459

Bullous Drug Reactions.

Maja Mockenhaupt1.   

Abstract

Bullous drug eruptions are infrequent, but because they pose a challenge both to affected patients and to treating physicians they are considered to be the most severe cutaneous adverse reactions (SCAR). It is important to recognize these conditions and to differentiate them from other clinical entities involving blister formation. There may be early signs and symptoms that indicate a severe bullous drug eruption even before blisters and erosions of the skin and mucous membranes become obvious. Once the diagnosis is suspected, appropriate diagnostic procedures and adequate management must be initiated. The latter includes identification of the potentially inducing drug, although it should be taken into account that not all cases of bullous eruptions are drug-induced. In cases with drug causality the potentially culprit agent must be withdrawn, while in cases with other aetiology the underlying condition, e.g. an infection, must be treated appropriately. In addition to best supportive care, immunomodulating therapy may be considered.

Entities:  

Keywords:  Stevens-Johnson syndrome; generalized bullous fixed drug eruption; toxic epidermal necrolysis; severe cutaneous adverse reaction

Mesh:

Year:  2020        PMID: 32039459      PMCID: PMC9128954          DOI: 10.2340/00015555-3408

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   3.875


  96 in total

1.  SCORTEN: a severity-of-illness score for toxic epidermal necrolysis.

Authors:  S Bastuji-Garin; N Fouchard; M Bertocchi; J C Roujeau; J Revuz; P Wolkenstein
Journal:  J Invest Dermatol       Date:  2000-08       Impact factor: 8.551

2.  The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre.

Authors:  H Y Lee; Y L Lim; T Thirumoorthy; S M Pang
Journal:  Br J Dermatol       Date:  2013-12       Impact factor: 9.302

3.  Fixed eruptions: causative drugs and challenge tests.

Authors:  K Kauppinen; S Stubb
Journal:  Br J Dermatol       Date:  1985-05       Impact factor: 9.302

4.  ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis.

Authors:  B Sassolas; C Haddad; M Mockenhaupt; A Dunant; Y Liss; K Bork; U F Haustein; D Vieluf; J C Roujeau; H Le Louet
Journal:  Clin Pharmacol Ther       Date:  2010-04-07       Impact factor: 6.875

5.  Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features.

Authors:  Yung-Tsu Cho; Jheng-Wei Lin; Yi-Chun Chen; Chia-Ying Chang; Cheng-Hsiang Hsiao; Wen-Hung Chung; Chia-Yu Chu
Journal:  J Am Acad Dermatol       Date:  2014-01-02       Impact factor: 11.527

6.  Bullous fixed drug eruption masquerading as recurrent Stevens Johnson syndrome.

Authors:  Farid M Dharamsi; Michael D Michener; Jennifer Warner Dharamsi
Journal:  J Emerg Med       Date:  2014-11-27       Impact factor: 1.484

Review 7.  The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis.

Authors:  Y-C Huang; Y-C Li; T-J Chen
Journal:  Br J Dermatol       Date:  2012-08       Impact factor: 9.302

8.  CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Esther Morel; Salvador Escamochero; Rosario Cabañas; Rosa Díaz; Ana Fiandor; Teresa Bellón
Journal:  J Allergy Clin Immunol       Date:  2010-02-04       Impact factor: 10.793

9.  Antishear therapy for toxic epidermal necrolysis: an alternative treatment approach.

Authors:  Amir H Dorafshar; Sara R Dickie; Alvin B Cohn; Joyce K Aycock; Annemarie O'Connor; Avery Tung; Lawrence J Gottlieb
Journal:  Plast Reconstr Surg       Date:  2008-07       Impact factor: 4.730

10.  Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe.

Authors:  Emmanuelle Génin; Martin Schumacher; Jean-Claude Roujeau; Luigi Naldi; Yvonne Liss; Rémi Kazma; Peggy Sekula; Alain Hovnanian; Maja Mockenhaupt
Journal:  Orphanet J Rare Dis       Date:  2011-07-29       Impact factor: 4.123

View more
  3 in total

1.  [Ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis].

Authors:  Argyrios Chronopoulos; Maja Mockenhaupt; Uwe Pleyer
Journal:  Ophthalmologe       Date:  2021-03-16       Impact factor: 1.059

2.  Clonal expansion of CD4+CD8+ T cells in an adult patient with Mycoplasma pneumoniae-associated Erythema multiforme majus.

Authors:  Sarah M Volkers; Christian Meisel; Dorothea Terhorst-Molawi; Guido J Burbach; Dirk Schürmann; Norbert Suttorp; Leif E Sander
Journal:  Allergy Asthma Clin Immunol       Date:  2021-02-10       Impact factor: 3.406

Review 3.  Vesiculobullous skin reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature.

Authors:  P Coto-Segura; M Fernández-Prada; M Mir-Bonafé; B García-García; I González-Iglesias; P Alonso-Penanes; M González-Guerrero; A Gutiérrez-Palacios; E Miranda-Martínez; F Martinón-Torres
Journal:  Clin Exp Dermatol       Date:  2021-09-02       Impact factor: 4.481

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.